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1. Introduction
Leishmaniasis is an infection caused by a parasite from Leishmania genus, which can manifest
itself through different forms: cutaneous (with skin ulcers) [1, 2], visceral (hepato and spleno‐
megaly) [3], and diffuse integumentary form (injuries beyond the superficial skin barrier,
hitting cartilages and deeper connective tissues) [4]. Leishmaniasis vectors are diptera from
Psychodida family, which includes hematophagous from Phlebotomus genus (Old World) and
Lutzomuyia genus (New World), with wide distribution in warm and temperate climates [5]
(Figure 1).
In the New World, eight Leishmania species are responsible for men diseases: Leishmania
braziliensis, Leishmania guyanensis, Leishmania panamensis, Leishmania lainsoni, Leishma‐
nia mexicana, Leishmania amazonensis, Leishmania venezuelensis and Leishmania chagasi
[7]. Thus, leishmaniasis can be found in four continents, being considered endemic in 88
countries, of which 72 are in development [5].
Different protozoa species are able to live inside sand flies (insect vectors) from Phlebotomi‐
nae subfamily and vertebrate hosts. This parasite lives between two different types of hosts
due to its significant morphological changes. In vertebrate hosts, Leishmania is at amastigote
form without flagella and inside the digestive tract of the sand flies, the parasite is flagellated
and fusiform, and receives the name of promastigote, as shown in Figure 2.
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Figure 1. Distribution in Old World and New World of cutaneous (left, marked in orange) and visceral (right, marked
in purple) leishmaniasis. Affected areas marked according to the World Health Organization [6].
Figure 2. Leishmania sp (A) promastigote and (B) amastigote (right) forms.
In Figure 3, two important cellular structures used to identify the Leishmania parasites are
highlited in the first image - the nucleus, indicated by the letter N and the kinetoplast, indicated
by the letter K. These structures are kept in the distinct methacyclogenesis stages. After
completing the cycle modifications, Leishmania becomes able to infect mammalian cells.
Different forms of leishmaniasis are transmitted through the bite of female sand flies. The
transmission cycle begins when, during a bite, the mosquito ingests mammalian blood infected
with amastigote forms. Once installed in the digestive tract of the host, Leishmania passes
through the process of differentiation, methacyclogenesis, and the new form of the parasite,
promastigote, can be inject in mammalian blood again during a bite, thus completing the
disease transmission cycle (Figure 4).
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Figure 4. Life cycle of the parasite.
Figure 3. Different transition stages between (a) promastigote and (f) amastigote forms of Leishmania braziliensis.
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2. Current treatments
In 1912, Vianna [9] observed that the tartar emetic (an antimony compound) was effective in
the treatment of American Integumentary Leishmaniasis. Due to toxicity and serious collateral
damages associated to the tartar emetic use, i.e. gastrointestinal intolerance and cardiotoxic
effects, the trivalent antimonials (Table 1) were replaced by quinquivalent compounds (Table
2). In 1936, Schmidt introduced in medical therapy antimony (V) sodium gluconate, commer‐
cially known as Solustibosan® (Bayer) or Pentostam® (Glaxo Wellcome) [10, 11].
Structural form Chemical/commercial names
Antimony (III) potassium tartrate [11]/
Tartar emetic
Sodium antimony (III) bis (catechol – 3,5 – disulfonate)
[11]/
Stibophen, Repodral, Fuadina
Antimony (III) sodium thioglicolate [11]
Table 1. Chemical structure of trivalent antimonials used in medical clinic, with their respective chemical and
commercial names [5].
One of the most commonly used drugs is N-methylglucamine antimoniate, which are espe‐
cially effective in the treatment of cutaneous and visceral leishmaniasis. This drug provokes
fast regression of the clinical and hematological manifestations of the disease, as well as the
dead of the parasite [5]. However, due to its low dosages and discontinuous treatments, some
therapy failures, an increase of the resistant forms of the parasites started to show up [12-14].
The World Health Organization preconizes that antimonials dosages Should not trespass 20
mg/kg/day, and due to its elevated toxicity, the dosage of antimony ingested per day should
not be higher than 850 mg [12]. However, the N-methylglucamine antimoniate is rapidly
absorbed and about 90% of the antimony ingested is excreted through the kidneys in the firsts
48 hours [15]. Consequently, there is a necessity to administrate high doses of the drug, in
continuous regimen, so an elevated dosage of antimony is assured in the tissues, and therefore
the treatment efficacy is obtained.
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High doses of N-methylglucamine antimoniate generate a various diversity of collateral
effects, such as nephritis, gastrointestinal, cardiovascular and respiratory disturbances. In
some cases, besides destroying the parasites, some patients are led to death [11]. The antimony
can still be detected in the hair of the patients a year after the treatment is finished [16]. The
toxicity of antimony can be explained by the fact that there are some evidences describing that
a metabolic conversion happens inside the macrophages transforming antimony V (Sb5+) in
antimony III (Sb3+) [13] and the antimony III is proved to be more lethal to the Leishmania species
[5]. So the hypothesis is that the antimony V works as prodrug, and the conversion to antimony
III is what guarantee its efficacy after administration [17], and the antimony III interferes in
the β-oxidation process of fat acids of the parasites, as so in the glycolysis, taking the ATP to
a low level inside the cell [12]. This way, the antimony III would be responsible for the toxicity
of the drug as well as its therapeutic activity [18].
Besides antimonials, other medicines have been used in the treatment of the various forms of
leishmaniasis, among them can be found pentamidine, amphotericin B, paromomycin, and
miltefosine (Table 3) [5]. Pentamidine is also effective in the trypanosomiasis treatment [19]
and this drug is also highly toxic, showing as collateral effects hypoglycemia, hypotension,
cardiologic changes, nephrotoxicity and even death [12]. Amphotericin B is an antibiotic
produced by Streptomyces nodosus and can produce nephrotoxicity, depleting the potassium
and magnesium levels of the organism [20]. Paromomycin is an aminoglycoside antibiotic
active against Leishmania species in in vitro and in vivo forms. It is been highly tested in India,
where antimonial standard treatments are not effective [5]. Miltefosine is an alkyl phospholi‐
pidic anticancer drug and it is in intensive tests also in India. It is showing excellent results
and may be the first oral treatment against visceral leishmaniasis [21].
Proposed structural form Chemical/commercial name
N-methylglucamine antimoniate [10]/
Glucantime®; Meglumine antimoniate
Antimony (V) Sodium Gluconate [10, 12] or Sodium
Stibogluconate/
Pentostam®; Solustibosan®
Urea estibamine [11]/ Estibamine®
Table 2. Chemical structure of quinquivalent antimonials used in medical clinic [5].
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Structural form Chemical/commercial name
Pentamidine Isethionate [13]/
Lomidine
Amphotericin B [13]/ Fungizone
Miltefosine [21]
Paromomycin [13]/ Humatin
Table 3. Other chemicals used in leishmaniasis therapy, with their respective chemical and commercial names.
3. Alternative treatments
Association of some drugs used in leishmaniasis treatment within lipid vesicles called
liposomes is one of the alternatives used to reduce the undesirable effects. This association
increases the efficiency and the concentrations of these drugs in the tissues, reducing drasti‐
cally their toxicity [22, 23]. The mechanism that could explain the effectiveness of liposomes
is that they inhibit oxygen consumption by the parasite membrane [24].
One practical exemple of this association happens with Amphotericin B, a compound used for
the treatment of calazar patients that are resistant to pentamidine. Amphotericin B can be toxic
because they can associate with human cell cholesterol as they do to the ergosterol in the
parasite plasmatic membrane [6]. To reduce this inappropriate recognition, there are some
commercial formulations that associate the Amphotericin B to lipids (Ambisome, Abelcet,
Amphotec). Besides their effectiveness in reducing this drug toxicity, they are very expensive
and their use becomes basically impractical in poor countries [25].
However, there are some studies searching some low-cost methods of producing these drugs.
One example is a formulation with a similar lipid composition to Abelcet, but with some
different variables, such as conformation and molecular weight, that may influence the drug
release and action in the organism [26]. This formulation was found to be much more effective
and less toxic than Abelcet and, although it is less efficient than Ambisome, it is also less
expensive for use in leishmaniasis treatment.
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4. Vaccines against Leishmaniasis
Studies for the achievement of a vaccine for leishmaniasis immunization are accomplished
since 1940 [27]. In the firsts vaccination process against this disease, scientists didn’t know that
they were dealing with a microbian ill. This vaccine method was based in the injection of the
active wound secretion from one patient to another that was not ill.
From this vaccine, other techniques were developed aiming the raise of the prophylactic
efficiency and to avoid some troubles caused by the emergence of a wound. Thus, specialized
literature reports four types of vaccines against different types of leishmaniasis: the vaccine
based on dead parasites, the vaccine based on living but attenuated parasites, the vaccine with
antigenic fragments, and the genic vaccine based on DNA [28].
In a few countries, some clinical trials were already performed but none of the vaccines showed
a level of efficiency higher than 80%, a fact that makes unfeasible human tests. This lack of
security may be associated to the differentiation between Leishmania species [29], and this
differentiation hampers the accomplishment of a wide immunization field.
New investments to the manufacture of a vaccine against leishmaniasis depend on an active
biomass of these protozoa. This way, when in contact with the target it may generate an
immunological response without generating the disease. But nowadays, the methods for
obtaining this biomass [30, 31] are very expensive with low profitability, since it generates a
very small sample with an inefficient outcome.
5. New treatment proposals
Due to intense collateral effects, lots of people who are infected with leishmaniases refuse
treatment, and there is the need to new alternative treatments. One of the new possibilities in
study nowadays uses natural rubber (NR) membranes with metallic nanoparticles (MNPs)
such as silver and gold (SNPs and GNPs, respectively). NR membranes are used as an active
support to the MNPs reduction process using precursor salts to obtain metallic particles, and
that means that the NR membrane works as a reducing agent as well as a stabilizer for MNPs.
When a promastigote population of Leishmania braziliensis is in the presence of pure natural
rubber membranes, there is a significant increase in the log phase of the cells, constituted by
a large number of cells at the division process. In the 27th hour after inoculation, the parasite
colony remains stable, without large variations in the population cells. In this phase, called
stationary phase, the promastigote cells start morphophysiological transformations known as
metacyclogenesis. With the end of the stationary phase, an environmental saturation happens
with cell waste and lack of nutrients, resulting in the death of cells, phase known as fall.
This decrease could be explained by the natural dynamics of promastigotes in the culture
medium. It is expected that after 150 hours, this decrease in the population number occurs
because of nutritional deficit and saturation of the cellular environment with cellular excreta
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generated during the period of growth log and stationary phase, but the presence of nano‐
particles anticipates the drop in the number of the parasites, probably because these metal
components stop the absorption of nutrients of the environment through permeases and
transplasmalema transport channels.
However, when promastigotes interact with natural rubber membranes impregnated with
silver nanoparticles, a stretch of the first metabolic phase is seen, only with a non-significant
growth. In figure 5 is possible to see that the decrease in L. braziliensis is proportional to the
increase of silver concentrations in the NR membrane.
Silver nanoparticles toxicity is well known, and although death of the promastigotes may
occur, it is believed that changes in the physiological maturation process, such as drastic
changes in the surface glycoproteins, happen to the microorganism cell. In that way, the NR
membranes with silver nanoparticles when put in the protozoa medium is capable of sepa‐
rating the cells without killing the whole population, eliminating only the ones which did not
finalized their metacyclogenesis and are highly infective to the hosts (Figure 6). Immature cells
that are not able to generate a disease are kept intact, and this process is what generates an
important biomass to a future study focus a vaccine against this disease.
Figure 5. Populational growth of Leishmania braziliensis promastigotes in contact with natural rubber membranes
and natural rubber membranes impregnated with silver nanoparticles using in situ reduction.
Natural rubber membranes containing GNPs (NR/Au) also decrease the population growth
rate, showing a lower index of living promastigotes (attached to the membrane surface)
depending on the amount of nanoparticles deposited in the membrane surface. Formation and
growth of the GNPs within the NR membranes, by reduction of Au3+, was monitored following
the Plasmon absorption band. Reducing agents for GNPs formation are likely to be the
carboxylic functional groups present in the NR. Nanoparticle, which produces an increase of
the intensity of the distinctive plasmon absorption band of GNPs centered at approximately
560 nm, as shown in Figure 7 [33].
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Figure 7. UV-Vis spectroscopy of natural rubber/gold nanoparticles prepared at different gold reduction times, com‐
pared to raw natural rubber membrane (preparation of the membrane annealed at 65 °C).
Figure 6. Separation Process of Leishmania in contact with NR membranes with silver (Ag) nanoparticles; (a) and (b)
NR/Ag membranas in culture medium; (c) Leishmania braziliensis in contact to NR/Ag membranes; (d) Separated pro‐
tozoa attached to NR/Ag membranes.
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Analyses by scanning electron microscopy (ESEM) were performed for natural rubber
membranes with gold nanoparticles, obtained at a reduction time of 30 min (Figure 8).
Apparently, there is a homogenous distribution of nanoparticle occupying the entire surface
of the membrane, but by amplifying the images, one can observe the formation of many
nanoparticles in sites, and among them, nanoparticles dispersed on the surface of the poly‐
meric matrix. In Figure 8 (d) the small spherical nanoparticles can be seen agglomerated over
reduction sites, forming aggregates at an exorbitant amount. Nanoparticles sizes were
measured and are very similar, with an average of approximately 48 nm. These results are in
agreement with the analysis by UV-Vis spectroscopy.
Figure 8. SEM analysis of NR/Au membrane obtained at 30 minutes of reduction. Magnification of (a) 200 times; (b)
1,000 times; (c) 20,000 times; (d) 100,000 times.
Natural rubber membranes, with colloidal incorporation of gold nanoparticles, were synthe‐
sized by in situ method (NR/Au) at different reduction times, in order to evaluate the physio‐
logical behavior of L. braziliensis promastigotes cultured in axenic medium, in a colony of seven
weeks old, evaluating the increase kinetics in relation to the permanence time of the mem‐
branes in the culture medium as a function of reduction time and temperature of preparation
of natural rubber membranes.
It was observed that the inclusion of NR/Au membrane in culture generates a delayed onset
of growth in culture until about 24 hours, with a reduction in the development population
proportional to the time reduction of the gold nanoparticles. It is also noted that the NR/Au
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120 min. membrane presents the best results with regard to growth inhibition of promastigote
population in culture medium. NR/Au 30 min membrane has a sharper decline in curve
kinetics attributable to death of promastigotes from 120 hours. Upon analysis completion of
growth medium, the membranes prepared for times of 30, 60 and 120 minutes showed similar
results, with the number of promastigotes in solution smaller than inserted into the initial
population.
According to the results the best allowed reduction time is 120 minutes, due to its greater
population growth inhibition, and was then assessed the influence of the thermal treatment
by the casting preparation method of membrane natural rubber annealed at 60, 80 and 120 °C,
and then used as substrates for the reduction of nanoparticles. Results obtained for the kinetics
of increase in solution are shown in Figure 9.
Figure 9. Analysis of the kinetics of increase of promastigotes in solution in the presence of natural rubber mem‐
branes prepared by the casting method, at temperatures of 65, 80 and 120 °C, and then incorporated gold nanoparti‐
cles to the time reduction of 120 minutes.
It is observed that with increasing of thermal treatment temperature in the preparation of NR
membranes the population growth factor in culture decreases, reaching scores lower than
2x105 promastigotes (less than half of the inoculum) to membranes prepared at 120 °C at a
reduced nanoparticles to 120 minutes. It is known from promastigotes reactivity with carbox‐
ylic and nitrogenated groups, the same reactive groups and assigned to the reduction of
nanoparticles. Higher the temperature of thermal treatment used in the preparation of NR
membranes, smaller the amount of nanoparticles embedded in the membrane surface,
attributed to the fact that there is further degradation of the active components of the mem‐
brane with increasing temperature. Thus, it is attributed the decrease in population growth in
solution to generate more reactive nanoparticles or selective proteins contained in the culture
medium, inhibiting the development of promastigotes, and may also be linked to decreasing
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of active cores on the membrane surface, or even liberation of radicals in the culture medium
attributed to membrane preparation temperature, but the level of promastigotes in culture
medium still remains considerable, so that in an attempt to develop a smart skin bandage
incorporated into methylene blue molecules on Au particles to photodynamic treatment, due
to the drug photosensitivity.
Membranes of pure natural rubber and with incorporation of gold nanoparticles and methyl‐
ene blue were inserted in the culture medium and the behavior of L. braziliensis promastigotes
were evaluated through the population growth kinetics and morphophysiological analysis.
Results regarding to population growth obtained for protozoan eluted to membranes prepared
at 120 °C of thermal treatment are presented in Figure 10.
Figure 10. Molecular spectroscopy in UV-Vis region of natural rubber membranes with gold nanoparticles for reduc‐
tion time of 120 min and functionalization with methylene blue molecules, compared to pure natural rubber mem‐
branes.
To improve the studies, blue methylene was incorporated to the NR membrane. This incor‐
poration does not show toxic interaction with promastigotes, since the population growth
usually develops when inserted NR/MB membranes. Moreover, when irradiated culture
media containing BM molecules, a deficit in the population growth is observed. For NR/MB
membranes irradiated with blue light total elimination of promastigotes is observed in about
120 hours, whereas when MB molecules deposited on gold nanoparticles this time decreases
to about 60 hours. This fact is attributed to the amplification effect of surface commonly
evaluated by micro-Raman spectroscopy, so that the metallic particles act as sites for amplifi‐
cation of energy absorbed by the anchored molecules.
The electrons assume an excited energy state, and during the release of the absorbed energy
active radicals are generated, with interaction with the environment where are MB molecules.
In the first instance, electrons from MB molecules, when returning to the ground state emit
enough energy to excite the oxygen present in the medium converting to superoxides or
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peroxides radials. This transfer may occur also by interaction with hydrogen atoms present in
other molecules to form radicals, e.g. hydroxyl, also with potential toxic to cells, or as in this
case, the promastigotes. If the emission energy is derived from a transition to a triplet state of
the photosensitizer, one can obtain the formation of a singlet oxygen molecule and an oxidizing
agent more toxic to cells [34-38].
6. Conclusion
Membranes with metal nanoparticles significantly influences the development of the proto‐
zoan L. braziliensis, thus they can be used for different applications.
Membranes with SNPs can separate the cells at different stages of maturation. In this case, we
obtain a biomass feasible to manufacture a vaccine for the purpose of immunization against
leishmaniasis.
Membranes with GNPs can used for a possible treatment of cutaneous leishmaniasis, once the
cell death is cause due to interaction between the gold and protozoan. NR/MB membranes can
be direct to the photosensitive treatment of lesions and so accelerate the closing of the same.
Thus, membranes with metallic nanoparticles are a viable and the low cost for both the
immunization procedure and in the treatment process because the disease is already estab‐
lished. In addition, treatment with the application of membranes with MNPs dramatically
reduces the side effects caused by conventional treatment.
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